Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events

Research output: Contribution to journalJournal articleResearchpeer-review

  1. 30-day mortality in frail patients undergoing cardiac surgery: the results of the frailty in cardiac surgery (FICS) copenhagen study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Relationship Between Invasive Hemodynamics and Liver Function in Advanced Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Atrial fibrillation and anticoagulation in patients with breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A national needs assessment study to determine procedures for simulation-based training in cardiology in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Contemporary practice of CRT implantation in scandinavia compared to Europe

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of acute myocardial infarction-related cardiogenic shock during corona virus disease 19 (COVID-19) pandemic

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Catheter ablation and mortality, stroke and heart failure readmission with atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prevalence and incidence of various Cancer subtypes in patients with heart failure vs matched controls

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background. Liraglutide, a glucagon-like peptide-1 agonist, is used for treatment of type 2 diabetes and has beneficial cardiovascular properties. However, treatment increases heart rate (HR) and possibly the risk of cardiovascular events in chronic heart failure (CHF) patients. We investigated potential associations between HR changes and clinical, laboratory and echocardiographic parameters and clinical events in liraglutide treated CHF patients. Methods. This was a sub-study of the LIVE study. CHF patients (N = 241) with a left ventricular ejection fraction ≤45% were randomised to 1.8 mg liraglutide daily or placebo for 24 weeks. Electrocardiograms (N = 117) and readouts from cardiac implanted electronic devices (N = 20) were analysed for HR and arrhythmias. Results. In patients with sinus rhythm (SR), liraglutide increased HR by 8 ± 9 bpm (pulse measurements), 9 ± 9 bpm (ECG measurements) and 9 ± 6 bpm (device readouts) versus placebo (all p<.005). Increases in HR correlated with liraglutide dose (p=.01). HR remained unchanged in patients without SR. Serious cardiac adverse events were not associated with HR changes. Conclusions. During 6 months of treatment, HR increased substantially in CHF patients with SR treated with liraglutide but was not associated with adverse events. The long-term clinical significance of increased HR in liraglutide treated CHF patients needs to be determined.

Original languageEnglish
JournalScandinavian cardiovascular journal : SCJ
Volume54
Issue number5
Pages (from-to)294-299
Number of pages6
ISSN1401-7431
DOIs
Publication statusPublished - Oct 2020

ID: 59671775